TMDX
TransMedics Group, Inc.
NASDAQ · Healthcare · Medical - Devices · US
$65.99
−1.68%Year over year
Reported trailing growth
- Revenue
- +25.8%
- EBITDA
- +16.3%
- EBIT
- +6.6%
- EPS
- +108.5%
- Free cash flow
- +355.5%
- Operating cash flow
- +26.6%
Forward estimates
Based on analyst estimates
- Revenue
- +25.4%
- EBITDA
- +54.6%
- EPS
- -52.8%
Three-year CAGR
- Revenue
- +86.4%
- EBITDA
- +112.3%
- EBIT
- +189.6%
- Net income
- +436.6%
- EPS
- +423.4%
- Free cash flow
- +265.0%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026